Relative Abundance and Detection of Pseudomonas aeruginosa from Chronic Wound Infections Globally

Abstract

Pseudomonas aeruginosa is a difficult-to-treat pathogen that is frequently involved with chronic wound infections. Here, we conducted a literature search of world-wide studies published between 2005 and 2022 that described the microbiological profiles of chronic wound infections. For each continent, a hierarchy of pathogens was created to define the organisms that were most frequently isolated in each region. Except for South America, P. aeruginosa was the second most common organism in each major continent, with Staphylococcus aureus being the most abundant pathogen overall. When individual countries were evaluated, P. aeruginosa was the most frequently isolated organism in several Southeast Asia nations including India and Malaysia. P. aeruginosa was less commonly isolated from diabetic foot infections in North America, Europe, and Africa in comparison to other types of chronic wound infections. Additionally, the Levine wound swab technique may be a quick and painless way to isolate P. aeruginosa from wound infections, but the isolation of P. aeruginosa does not seem to be an informative predictor of the patient’s clinical course. A multivariate risk assessment that accounts for the regional frequency of P. aeruginosa isolation may be an appropriate way to guide empiric management of chronic wound infections.

HOCl-producing Electrochemical Bandages for TreatingPseudomonas aeruginosa-Infected Murine Wounds

“…P. aeruginosa is a commonly isolated chronic wound pathogen that is notorious for its intrinsic resistance and rapid acquisition of resistance to multiple classes of antibiotics. 21 Additionally, P. aeruginosa is a prominent biofilm producer, further promoting its recalcitrance to traditional antibiotic treatment and clearance by the host immune system, delaying healing when present in wounds. 5, 22 Here, a novel e-bandage was tested for the in situ delivery of a potent biocide, HOCl.…”

Silversol®(a colloidal nanosilver formulation) inhibits growth of antibiotic-resistantStaphylococcus aureusby disrupting its physiology in multiple ways

“…Silversol is already in clinical use for multiple therapeutic purposes e.g., management of oral health (Tran et al, 2019), skin diseases, burns, diabetic ulcer, and wound-care/ wound-disinfection (https://www.rxsilver.com/index_htm_files/ABLSilversafety.pdf). S. aureus being one of the common clinical isolates (Reyes et al, 2023; Phan et al, 2023), we attempted to gain insight into Silversol’s antibacterial activity against this pathogen.…”

Adaptation ofPseudomonas aeruginosato repeated invasion into a commensal competitor

“…Rapid adaptation to the host environment is likely especially important for environmental opportunistic pathogens like P. aeruginosa, for whom the human host environment represents one of many niches it has the potential to survive in (7)(8)(9)(10). P. aeruginosa is frequently implicated in chronic wound infections (11), serious short-term respiratory infections (12), and can also colonise the lungs of patients with bronchiectasis or cystic fibrosis resulting in recurrent long-term infections (13). S. epidermidis is suggested to contribute to pathogen colonisation resistance in the microbiome through a number of mechanisms (14,15), including via the secretion of bacteriocins with inhibitory activity (16,17) and via proteases that can inhibit biofilm formation, as demonstrated with Staphylococcus aureus (18).…”